BioSpace News Archive

Business

Regeneron and Alnylam Ink $1 Billion Eye and Central Nervous System R&D Deal

Under the terms of the agreement, Regeneron is paying $400 million upfront to Alnylam and acquiring another $400 million in equity at a price per share of $90, or 4.44 million common shares.

April 8, 2019
·
3 min read
·
Mark Terry
Policy

Celgene and Acceleron File BLA for Potential Blockbuster Blood Disease Treatment

Celgene and its developmental partner Acceleron Pharma are eying a potential U.S. Food and Drug Administration approval of a blood-disease treatment.

April 8, 2019
·
2 min read
·
Alex Keown
Policy

PBM Executives to Face the Congressional Hot Seat This Week

Representatives from Cigna, CVS, OptumRx, Prime Therapeutics and Humana will meet with Congress regarding prescription drug prices.

April 8, 2019
·
3 min read
·
Alex Keown
Drug Development

Eye Test May Offer Early Diagnosis for Alzheimer’s Disease

A new report published by researchers at Northwestern University offers the possibility of an early diagnostic test for Alzheimer’s disease—via an eye test.

April 8, 2019
·
3 min read
·
Mark Terry
Drug Development

United Therapeutics Abandons Pulmonary Hypertension Program After Failed Phase III Trial

Silver Spring, Maryland-based United Therapeutics announced that its esuberaprost tablet did not meet its primary endpoint in the BEAT Phase III clinical trial in patients with pulmonary arterial hypertension (PAH).

April 8, 2019
·
2 min read
·
Mark Terry
Business

Seattle’s LabConnect: An Interview With Chief Development Officer Jeff Mayhew

Jeff Mayhew, LabConnect’s Chief Development Officer, took time to speak with BioSpace about the company and the Seattle area. Mayhew is also one of the founders of LabConnect, which was started in 2002 and relocated to Seattle in 2004.

April 8, 2019
·
4 min read
·
Mark Terry
Policy

Dubai Government Workshop joins whole UAE in celebration of World Health Day

Activities held in partnership with Dubai Health Authority

April 8, 2019
·
2 min read
Drug Development

TLC Announces Full Enrollment in Part 1 of Phase II Trial of TLC590 for Postsurgical Pain Management following Bunionectomy

TLC announced the earlier-than-scheduled full enrollment in Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.

April 8, 2019
·
5 min read
Drug Development

Failed Allergan Antidepressant May Find New Life in Treating Opioid Withdrawal

In early March, Allergan reported that rapastinel, its experimental adjunctive treatment for major depressive disorder, failed to hit endpoints in a late-stage trial.

April 8, 2019
·
2 min read
·
Alex Keown
Business

Audentes Therapeutics Licenses Muscular Dystrophy Tech From Nationwide Children’s Hospital

San Francisco-based Audentes Therapeutics signed a licensing agreement and collaboration deal with Nationwide Children’s Hospital to expand its pipeline for vectorized antisense treatments for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1).

April 8, 2019
·
3 min read
·
Mark Terry